[The progress in dermatomyositis (ProDerm) study : First phase III study on the use of intravenous immunoglobulins in dermatomyositis]

Z Rheumatol. 2023 Oct;82(8):688-691. doi: 10.1007/s00393-023-01376-9. Epub 2023 Jun 2.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Polymyositis*

Substances

  • Immunoglobulins, Intravenous